Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dogan Bayram

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Chemotherapy (Florence, Italy)|February 20, 2025
Pembrolizumab associated immune thrombocytopeniaPerihan Perkin, Serhat Sekmek, Dogan Bayram, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 14, 2024
Letrozole-induced reversible acute heart failureSerhat Sekmek, Dogan Bayram, Ismet Seven, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 11, 2023
Cabozantinib-induced heart failureSerhat Sekmek, Dogan Bayram, Gokhan Ucar, et al.
Oncology Research and Treatment|December 1, 2024
Prognostic Significance of HER2 Positivity in Endometrium CancerSerhat Sekmek, Dogan Bayram, Irfan Karahan, et al.
Scientific Reports|May 9, 2024
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatmentMurat Bardakci, Hilal Karakas, Dogan Bayram, et al.
Journal of Chemotherapy (Florence, Italy)|September 11, 2025
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 7, 2024
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter studySerhat Sekmek, Irfan Karahan, Gokhan Ucar, et al.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Chemotherapy (Florence, Italy)|February 20, 2025
Pembrolizumab associated immune thrombocytopeniaPerihan Perkin, Serhat Sekmek, Dogan Bayram, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 14, 2024
Letrozole-induced reversible acute heart failureSerhat Sekmek, Dogan Bayram, Ismet Seven, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 11, 2023
Cabozantinib-induced heart failureSerhat Sekmek, Dogan Bayram, Gokhan Ucar, et al.
Oncology Research and Treatment|December 1, 2024
Prognostic Significance of HER2 Positivity in Endometrium CancerSerhat Sekmek, Dogan Bayram, Irfan Karahan, et al.
Scientific Reports|May 9, 2024
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatmentMurat Bardakci, Hilal Karakas, Dogan Bayram, et al.
Journal of Chemotherapy (Florence, Italy)|September 11, 2025
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 7, 2024
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter studySerhat Sekmek, Irfan Karahan, Gokhan Ucar, et al.
Scientific Reports|November 30, 2024
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studySerhat Sekmek, Sema Nur Ozsan Çelebi, Dogan Bayram, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Pageof 1